Decreased insulin-stimulated glucose uptake and Akt phosphorylation in myotubes from severely obese donors with type 2 diabetes. by Siril S. Bakke (705734)

Resveratrol decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more efficiently than 5-ASA. by Diana Serra (455187)

Intranasal administration of perindopril decreases amyloid plaques and CD11b staining in the cortex of 3-month old 5XFAD mice. by Nofar Torika (3169497)

Intranasal administration of telmisartan decreases amyloid plaques and CD11b staining in the cortex of 3-month-old 5XFAD mice. by Nofar Torika (3169497)

The Activation Effects of Low Level Isopropyl Alcohol Exposure on Arterial Blood Pressures Are Associated with Decreased 5-Hydroxyindole Acetic Acid in Urine by Zhiqiang Zhao (201543)

Hepatic irradiation decreases the proportion of DX5^–TRAIL⁺ lrNK cells for up to two months. by Ryosuke Nakano (4557097)

“…NK cells were divided into DX5^–TRAIL⁺ lrNK cells and DX5⁺TRAIL⁻ cNK cells. …”

Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

PI(3)P and VPS34 lipid kinase activity is decreased in <i>Becn1</i> deficient MEFs. by Nicole C. McKnight (638437)

“…PI(3)P concentration is determined by comparison to a standard curve. Quantification of 450 nm absorbance of control, <i>Becn1</i> deficient, and <i>Becn1</i> revertant MEFs (6,5,6 replicates); statistics using a one-tailed t-test p = 0.0032, 0.0336. …”

Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

Decreased ratio of GSH/GSSG in <i>Slc1a1-</i>HET mice. by Parisa Afshari (4423141)

Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: